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We recently proposed that alcoholics suffer from a functional defect 
within the basal gangliallimbic striatum or its modulation by dopa- 
minergic projections from the ventral tegmentum, and that inhibition 
of striatal output caused by the prodopaminergic effects of alcohol 
ingestion induces or exacerbates craving and impaired control over 
alcohol consumption in alcoholic individuals. To test this hypothesis, 
16 subjects with a diagnosis of alcohol dependence or abuse were 
studied in a double-blind, placebo-controlled experiment in which 
the effects of the D-2 antagonist haloperidol on measures of craving 
and impaired control were assessed before and after administration 
of a priming dose of alcohol. Subjects were pretreated with 0.015- 
0.025 mg/kg haloperidol (experimental condition) or 2 ml normal 
saline (control condition), and subsequently consumed 0.4-0.6 g/kg 
ethanol as their preferred alcohol-containing beverage. Significant 
increases in subjectively rated craving for alcohol and perceived 
difficulty resisting additional alcohol consumption occurred following 
the priming dose of alcohol when subjects were pretreated with 
saline. In contrast, no significant changes in reported ability to resist 
additional alcohol occurred when subjects were pretreated with 
haloperidol, and reported levels of craving decreased relative to 
baseline following haloperidol pretreatment. Subjects also con- 
sumed about 25% less optionally available alcohol when pretreated 
with haloperidol than when pretreated with saline. These findings 
support the hypothesis that craving and impaired control are induced 
or exacerbated by the prodopaminergic effects of alcohol consump- 
tion. 
Key Words: Dopamine, D-2 Antagonists, Basal Ganglia, Reinforce- 
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alcohol consumption. In a recent review,2 we proposed 
that craving for alcohol and impaired control over its 
consumption in these individuals may result from a func- 
tional defect within the limbic striatum or its modulation 
by dopaminergic projections from the ventral tegmentum; 
and that inhibition of striatal output caused by the pro- 
dopaminergic effects of alcohol ingestion induces or ex- 
acerbates craving and impaired control over alcohol con- 
sumption in alcoholic individuals. The reader is referred 
to this review for a detailed discussion of the background 
and support for this hypothesis. Excellent overviews by 
Koob3 of the anatomy, pharmacology, and function of 
reward pathways, and by Samson et a14 of the role of 
mesolimbic dopamine in ethanol self-administration also 
provide very useful background material. 
Our review of the literature supported the hypothesis 
that alcoholics (see footnote to title) may suffer from a 
neurophysiological dysregulation such that: 
I. (1 )  Craving for alcohol or obsession-like thoughts 
about drinking are induced or exacerbated by a neuronal 
overactivity within a reciprocally excitatory frontothal- 
amic circuit; (2) neuronal activity within this frontothal- 
amic circuit is normally damped by an interposed inhibi- 
tory circuit involving the nucleus accumbens and limbic 
portions of the caudate nucleus (collectively, striatoac- 
cumbens) and the ventral pallidum; (3) impaired function- 
ing of this interposed inhibitory circuit will lessen the 
ability of the alcoholic to control cravings for alcohol or 
obsession-like thoughts about drinking; and (4) decreased 
control over these thoughts promotes their behavioral 
expression; that is, heavy or compulsive-like drinking. 
11. Acute alcohol ingestion or-as a conditioned re- 
sponse to drinking-certain environmental or psycholog- 
ical cues normally associated with the individual’s heavy 
drinking result in: (1) an increase in dopaminergic-inhib- 
itory input from the ventral tegmentum to the striatoac- 
cumbens; (2) a resultant decrease in normal inhibitory 
feedback through the striatoaccumbens and ventral palli- 
dum to the thalamus; (3) a subsequent increase in recip- 
rocally excitatory orbitothalamic activity; and (4) a result- 
ant increase in craving for alcohol and/or a decrease the 
ability of the individual to control the behavioral expres- 
sion of these thoughts. This process may be the result of 
an underlying, possibly heritable neurophysiological defect 
in these neuronal systems. The neuronal circuitry impli- 
cated in this process is schematically depicted in Fig. 1, 
and is collectively referred to as the fronto-striato-pallido- 
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thalamo-frontal loop. Increases in dopaminergic activity 
within the nucleus accumbens have previously been im- 
plicated in the reinforcing properties of a l~ohol ,~ co- 
caine,5,6 and h e r ~ i n . ~ , ~  
Several tests of this hypothesis were proposed. In this 
study, we explore the effects of the D-2 antagonist halo- 
peridol on measures of craving and impaired control in 
alcoholic subjects before and after administration of a 
priming dose of alcohol. It is reasoned that if the proposed 
disinhibitory effects of ventral tegmental-striatoaccumbal 
dopamine release associated with alcohol consumption 
are correct, then pharmacological blockade of dopamine 
postsynaptic receptors in the striatoaccumbens should di- 
minish alcohol-induced craving, and diminish impaired 
control over drinking following alcohol consumption (or, 
conversely, increase the subject's ability to resist drinking 
additional alcohol). Furthermore, the effects of haloperi- 
do1 on craving and control over alcohol consumption 
should be independent of any subjectively perceived side 
effects of this medication. 
Past research has shown that administration of D-2 
antagonists can decrease alcohol withdrawal symptoms 
and withdrawal-associated craving in the clinical settings- 
'' and decrease ethanol intake in free-feeding  animal^.^." 
Voluntary ethanol consumption in both animals and hu- 
mans has also previously been reported to be decreased 
following administration of the D-2 agonists bromocryp- 
tine and apomorphine: this seemingly paradoxical effect 
may be the result of a medication-induced decrease in 
dopamine turnover secondary to presynaptic autoregula- 
tion, disruption of the normal high-rate drinking pattern 
during the initiation of a drinking bout, or side effects 
such as n a u ~ e a . ~ ~ ~ " ~  To our knowledge, however, this study 
is the first controlled study designed to determine whether 
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Fig. 1. Schematic diagram of the proposed relationship of neuronai activity to 
craving for alcohol and impaired control over alcohol Consumption associated with 
alcohol ingestion. Alcohol-induced augmentation (EtOH +) of dopaminergic-inhibi- 
tory input (t dopamine -) from the ventral tegmentum to the striatoaccumbens 
(shown by larger, bold print) results in a decrease in inhibitory feedback through 
the striatoaccumbens and ventral pallidum to the thalamus (shown by smaller print, 
lighter arrows) and a consequent increase in orbitothalamic reciprocal activity 
(shown by larger, bold print). The decrease in normal inhibitory feedback to the 
thalamus is hypothesized to result in an increase in craving for alcohol and/or a 
decrease in the ability of the alcoholic to control the behavioral expression of these 
thoughts. In either case, impaired control over alcohol consumption or compulsive 
drinking behavior would result. 
a D-2 antagonist can specifically reduce measures of al- 
cohol craving and impaired control following a priming 
dose of alcohol in human subjects who are not undergoing 
alcohol withdrawal. 
METHODS 
Sixteen subjects (10 men, 6 women; mean age 39, range 22-60) 
participated in this study. Subjects were selected on a volunteer basis 
from the University of Michigan and University of Alabama at Birming- 
ham outpatient alcohol-disorders clinics. All study subjects were, there- 
fore, engaged in, or entering a treatment program at the time of study 
participation, and all subjects returned to this program for continued 
treatment after completion of the experimental protocol. Informed con- 
sent was obtained from all subjects prior to study participation; this study 
was approved by the institutional review board and general clinical 
research center review board at each of the two universities. Subjects 
were paid $50 for study participation. Prior to study participation, all 
subjects received a physical exam and laboratory evaluation that included 
liver function tests, electrolytes, blood urea nitrogen, creatinine, complete 
blood count, and urine pregnancy test for women of child-bearing 
potential. 
All subjects satisfied DSM-111-R criteria for either alcohol dependence 
(n = 10) or alcohol abuse (n = 6). The last drink of alcohol taken by the 
subjects was between 1 and 14 weeks prior to participation in this project; 
therefore, neither individuals in the midst of alcohol intoxication or 
withdrawal, nor those who were achieving long-term abstinence were 
included in the study. All subjects reported that craving for alcohol and 
impaired control after one or two drinks were prominent components of 
their drinking history; this was quantified as follows: Subjects were asked: 
(1) "On a scale of 0 to 10, how much do you usually crave an alcoholic 
beverage 1 to 2 days after your last drink, if 0 is none at all and 10 is 
extreme?" and (2) "On a scale of 0 to 10, how difficult is it usually for 
you to stop drinking after just one or two small drinks, if 0 is extremely 
easy and 10 is extremely difficult?" A score of 5 or more for each question 
was required for participation. Degree of impaired control was also 
assessed from the clinical history: all subjects reported that they are 
generally unable to control their drinking once they have taken a drink, 
and that this problem occurred at least 10 times during the previous 
year. 
The following subjects were excluded from participation: subjects with 
coexistent DSM 111-R axis I psychiatric disorders, including other drug 
abuse; subjects having symptomatic medical problems or liver function 
tests greater than 150% of normal; subjects with a positive pregnancy 
test or any other reason to suspect pregnancy; and subjects taking any 
psychoactive medication or disulfiram within the previous 3 weeks. 
Ethnic and religious backgrounds were not factors in subject selection. 
The experiment was designed as a randomized-crossover, double- 
blind, placebo-controlled trial. All subjects were admitted for two vol- 
untary overnight stays in our general clinical research center, 48 hr apart; 
there was no experimental intervention between these admissions. Sub- 
jects were instructed to take nothing by mouth other than clear liquids 
during the 4 hr preceding study participation. Subjects understood the 
nature of the double-blind crossover experimental design, but were not 
told about the experimental hypothesis or the predicted effects of halo- 
peridol on the outcome measures until after completion of the experi- 
ment. 
Upon presentation for study participation, subjects received a urine 
drug screen and blood alcohol concentration (BAC) by breath analysis 
(Alco-Sensor-HI@ breath intoximeter) to ensure that the subjects were 
drug- and alcohol-free at the start of the experiment. An assessment 
questionnaire (Fig. 2) was then administered to each subject to assess 
currently perceived mood, craving for an alcoholic beverage, expected 
degree of difficulty that would be encountered resisting drinking an 
alcoholic beverage if offered (difficulty resisting drinking), level of intox- 
ication, thirst, capacity for experiencing pleasure, and sedation (assess- 
ment 0; Fig. 3). 
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Fig. 2. Assessment questionnaire for perceived mood, craving, resistance to 
drinking an alcoholic beverage if offered, intoxication, capacity for experiencing 
pleasure, thirst, and sedation. This questionnaire has been validated previously 
among alcoholic subjects, alcoholic subjects following exposure to alcohol, nonal- 
coholic subjects having major depressive disorder, nonalcoholic subjects having 
major depressive disorder who were taking tricyclic antidepressants, and normal 
subjects. The validation data showed the expected significant differences across 
groups in mood (item 1: depressed c alcoholic = normal; p s 0.01), craving and 
difficulty resisting drinking (items 2 and 3: alcoholic > depressed =. normal: p 5 
0.01), and capacity for experiencing pleasure (item 5: depressed < alcoholic = 
normal;p 5 0.01); significantly greater ratings for thirst and sleepiness in depressed 
subjects who were taking tricyclic antidepressants than among all other subjects 
who were medication-free (items 6 and 7: p c 0.02); and significant increases in 
craving, difficulty resisting drinking, and intoxication in alcoholic subjects following 
exposure to alcohol (items 2, 3, and 4: p s 0.01). 
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Fig. 3. Flow diagram showing the sequence of experimental interventions and 
assessments. 
Each subject then received haloperidol (diluted to 2 ml volume) or 2 
ml normal saline (placebo control) intravenously over approximately 15 
sec. The order of haloperidol/saline administration was randomly deter- 
mined by the investigational pharmacy: nine subjects received saline on 
the first night and haloperidol on the second, and seven subjects received 
haloperidol on the first night and saline on the second. In an effort to 
determine the dosage of haloperidol that would maximally affect meas- 
ures of craving and impaired control without producing confounding 
side effects, 0.0 15 mg/kg haloperidol was administered to the first four 
subjects, 0.020 mg/kg to the next eight subjects, and 0.025 mg/kg to the 
last four subjects. A starting dosage of 0.015 mg/kg haloperidol was 
chosen, because physiological effects in humans resulting from central 
D-2 postsynaptic receptor antagonism following haloperidol administra- 
tion become apparent in the 0.007 to 0.025 mg/kg dosage range.”-’’ 
Following haloperidol/saline administration, each subject rested for 15 
min to allow time for uptake of haloperidol into the brain2’ At this time, 
the assessment questionnaire was repeated (assessment l), and passive 
motor tone in the upper extremities was assessed on a scale of 0 to 4 (0 
= no resistance to passive motion, 4 = rigid). Additionally, subjects were 
asked whether they believed the injection contained placebo or active 
drug based on the perceived of the effects of the injection. 
Over the next 5 min, each subject was required to drink his or her 
favorite alcoholic beverage-that which he or she believed would most 
likely induce a desire for more of this beverage-containing 0.4 g/kg 
ethanol. When necessary, this beverage was fortified with 95% ethanol 
to limit the volume of beverage to 350 ml. The subject then rested for 
another 15 min, at which time the assessment questionnaire was read- 
ministered (assessment 2) and, immediately following, the BAC was 
again measured by breath analysis. 
The subject was then offered a choice of a second alcoholic beverage 
(same as the first but containing 0.2 g/kg ethanol), a glass of water, or 
no beverage. The subject was permitted to drink as much of the second 
alcoholic beverage as he or she desired over a period not to exceed 5 
min. The quantity of alcoholic beverage consumed at the end of the 5- 
min period (scored as 0 for choice of water or no beverage) along with 
the reported reason for choosing that quantity were noted. Fifteen 
minutes later, the assessment questionnaire was repeated for a final time 
(assessment 3), and the BAC was again measured. At this time, the 
subject was again asked whether he or she believed the injection con- 
tained placebo or active drug. 
Approximately 2 weeks following the experiment, each subject dis- 
cussed his or her reactions to the experiment-and especially to the 
alcohol administration-with the principal investigator (J.G.M.). The 
goal of this discussion was to use the knowledge gained from drinking in 
the controlled setting about the effects of alcohol consumption on mood, 
expectations, craving, and impaired control to help the subject under- 
stand more completely his or her reactions to alcohol consumption and 
reasons for using this drug. 
The outcome variables to be analyzed are the seven continuous 
assessment scales (questions 1-10, Fig. 2), the BACs following alcohol 
consumption, and the quantity of the second alcoholic beverage con- 
sumed. The assessment scales for craving and perceived ability to resist 
drinking an alcoholic beverage if offered (questions 2 and 3, respectively), 
and the quantity consumed of the second alcoholic beverage are the 
primary dependent variables, hypothesized to be specifically affected by 
haloperidol. The other assessment questionnaire items, BACs, ages of 
the subjects, subject gender, type of alcohol problem (abuse or depend- 
ence), and the duration of abstinence prior to study participation were 
treated as confounding variables. 
The change in each questionnaire-item rating from baseline (assess- 
ment 0) to each of the three postinjection assessments was determined 
for each subject under both the haloperidol and control conditions. The 
within-subject difference in change scores for each question at each 
assessment was compared between experimental conditions (haloperidol 
versus saline) using paired t tests. Within-subject paired t tests were also 
used to compare the effects of haloperidol and saline on motor tone and 
optional alcohol consumption. Analyses of variance were used to com- 
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pare the effects of saline and haloperidol on the primary dependent 
variables across time adjusted for intersubject variability. Analysis of 
covariance and linear regression were used to assess the effects of the 
potential confounding variables on the primary dependent variables. 
Order effects in the crossover design were evaluated using a t test for 
independent samples. All statistical tests use two-tailed probabilities at 
the 0.05 significance level. 
RESULTS 
Significant increases in subjectively rated craving for 
alcohol (question 2, Fig. 2) and difficulty resisting drinking 
(question 3, Fig. 2) occurred following the priming dose 
of alcohol (assessment 2) when subjects were pretreated 
with the saline control ( F  = 12.3, df1/31, p < 0.01; F = 
24, df 1/31, p < 0.001, respectively). Ratings of craving 
and difficulty resisting drinking remained significantly 
elevated at assessment 3 when subjects were pretreated 
with saline ( F =  7.4, 1/31, p = 0.01; F = 4.5, df 1/3, p = 
0.05, respectively). In marked contrast to these results, 
reported levels of craving and difficulty resisting drinking 
following pretreatment with haloperidol showed no signif- 
icant changes over time except for a significant decrease 
in craving relative to baseline at assessment 4 ( F  = 4.9, df 
1/3 1 ,  p = 0.05). The differential effects of haloperidol and 
saline on these outcome measures are apparent in the 
graphical display of the change scores for these variables 
shown in Figs. 4 and 5: the change scores for each question 
are derived by subtracting the assessment 0 (baseline) 
rating from each of the subsequent ratings for that ques- 
tion. For reference, mean craving scores at assessment 0 
were 4.2 preceding saline administration, and 5.1 preced- 
ing haloperidol administration ( p  = NS); and mean scores 
for difficulty resisting drinking at assessment 0 were 4.0 
preceding saline administration, and 4.9 preceding halo- 
peridol administration ( p  = NS). 
The average within-subject differences between the sa- 
line and haloperidol condition for craving (Fig. 4) were 
-1.2 at assessment 1 ( t  = -1.4, df = 15, p = 0.18), -2.8 
at assessment 2 ( t  = -3.1, df = 15, p = 0.007), and -2.9 
at assessment 3 ( t  = -3.0, df = 15, p = 0.009). The average 
within-subject differences between the saline and haloper- 
idol condition for difficulty resisting drinking (Fig. 5 )  were 
-0.9 at assessment 1 ( t  = -0.91, df = 15, p = 0.05), -2.4 
at assessment 2 ( t  = -3.4, df = 15, p = 0.004), and -2.8 
at assessment 3 ( t  = -2.6, df = 15, p = 0.02). Subjects 
also consumed an average of about 26% less optional 
(second beverage) alcohol when pretreated with haloperi- 
do1 than when pretreated with saline ( t  = -2.2, df = 15, p 
= 0.04; Fig. 6). 
There were no significant interaction effects between 
experimental condition (haloperidol versus saline) and 
time for any of the other outcome variables except for 
reported levels of sedation (question 7; Fig. 2). Following 
haloperidol administration, there were significant in- 
creases in reported levels of sedation relative to those 
reported following saline pretreatment. The average 
within-subject differences for sedation between the saline 
and haloperidol conditions were + 1.4 at assessment 1 ( t  
= 2.8, df = 15, p = 0.014), +2.4 at assessment 2 ( t  = 3.3, 
df = 15, p = 0.004), and +2.4 at assessment 3 ( t  = 3.5, df 
= 15, p = 0.003). Overt sedation, however, did not occur 
and there were no independent correlations between re- 
ported levels of sedation and craving, difficulty resisting 
drinking, or optional alcohol consumption (9 < 0.1, p > 
0.1 for all comparisons). Additionally, subjects generally 
had difficulty distinguishing injected haloperidol from 
saline: the agent administered was misclassified by the 
subjects in 34% of the cases at assessment 1 ,  and in 3 1 % 
of the cases at assessment 3 (x2 < 3.2, df = 1, p > 0.08). 
No significant differences were found in the relative 
effects of haloperidol on craving, difficulty resisting drink- 
ing, optional alcohol consumption, and sedation as a 
function of haloperidol dosage ( r 2  < 0.05, p > 0.2 for all 
comparisons), and no order effect of haloperidol/saline 
administration was found on the primary outcome vari- 
ables. Measured BACs averaged 50.7 mg% following the 
first drink of 0.4 g/kg ethanol, and 71.5 mg% following 
Fig. 4. Change scores for craving (question 2, Fig. 2) from baseline 
(assessment 0) to the assessments following injection (assessment l), 
following 0.4 g/kg beverage ethanol (assessment 2), and following 0.0- 
0.2 g/kg optional ethanol (assessment 3). Error bars show the standard 
errors of the mean (SEM). Mean craving scores at asSessment 0 were 
4.2 preceding saline administration, and 5.1 preceding haloperidol ad- 
ministration ( p  = NS). 
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Fig. 6. Quantity of optional alcoholic beverage consumed (g/kg EtOH) following 
saline administration (left) and haloperidol administration (right). 
the second drink of variable quantity (0-0.2 g/kg ethanol). 
All BACs were 0 at the start of the experiments. BACs 
were not independently associated with any of the primary 
outcome measures ( r2  < 0.05, p > 0.4). Additionally, no 
independent effects on the outcome variables were found 
as a function of subject age, sex, duration of abstinence, 
and type of alcohol problem (abuse versus dependence); 
it is, however, recognized that there may be insufficient 
statistical power to detect small effects from these factors. 
The reasons provided by the subjects for choosing to 
drink-or not to drink-the optional second beverage 
were informative. Following saline administration, all but 
two subjects consumed the full amount of optionally 
available alcohol. The two who did not reported that they 
simply “weren’t in the mood,” and that the ambient 
conditions were not conducive to enjoying additional 
alcohol. Following haloperidol administration, five sub- 
jects turned down the second drink entirely and one 
subject drank only one-quarter of this beverage. Three of 
these six subjects commented that their lack of desire to 
continue drinking alcohol was very unusual, but they 
Fig. 5. Change scores for perceived ability to resist drinking an alcoholic 
beverage if offered (question 3, Fig. 2), depicted as in Fig. 4. Mean 
resistance scores at assessment 0 were 4.0 preceding saline administra- 
tion, and 4.9 preceding haloperidol administration ( p  = NS). 
could not explain what was different about the current 
situation that would cause an unprecedented loss of inter- 
est in continued drinking; each suspected that this was an 
effect of the injection, although none were certain they 
had received haloperidol. Another subject who declined 
the second beverage said that his usual desire to continue 
drinking was simply absent, and he explained this on the 
basis of feeling “adequately relaxed” following the first 
drink. The sixth subject could find no explanation for 
refusal of the second beverage other than, “I just don’t feel 
like drinking anymore.” 
DISCUSSION 
The significant increases in subjectively rated craving 
for alcohol and difficulty resisting drinking that occurred 
following the priming dose of alcohol under the saline 
condition are consistent with the subjects’ reported histo- 
ries of impaired control over alcohol consumption in the 
naturalistic setting. In contrast, following pretreatment 
with haloperidol, subsequent exposure to alcohol did not 
cause the usual increases in craving and difkulty resisting 
drinking; reported levels of craving actually decreased 
relative to baseline at the final assessment period. That 
subjects also chose to drink less of the optionally available 
alcohol following haloperidol pretreatment than under the 
saline condition indicates that pretreatment with haloper- 
idol also affects the behavioral consequence of these sub- 
jective questionnaire measures. 
The findings of this study support the hypothesis that 
craving and impaired control in alcoholic individuals are 
induced or exacerbated by the dopaminergic effects of 
intoxication (and possibly a conditioned response to psy- 
chological or social cues associated with drinking), and 
that craving and impaired control can be diminished by 
administration of a pharmacologic D-2 antagonist prior 
to alcohol exposure. The study results are consistent with 
the effect of D-2 antagonists on free-access alcohol drink- 
EFFECT OF HALOPERIDOL IN ALCOHOLIC SUBJECTS 239 
ing in animals and support the hypothesis derived from 
these studies that the D-2 antagonist acts at the level of 
the nucleus accumbens and interferes with conditions 
necessary to maintain drinking during the early parts of 
the drinking The relative inability of the subjects to 
identify accurately whether they received haloperidol or 
placebo, the lack of a significant association between 
haloperidol-induced sedation and the primary outcome 
measures, the absence of other measurable side effects 
from haloperidol, and the reasons given by. the subjects 
for choosing to forego additional alcohol consumption all 
argue against the effect of haloperidol on craving, difficulty 
resisting drinking, and optional alcohol consumption 
being an epiphenomenon related to side-effects of this 
medication. 
Although the study findings are consistent with the 
hypothesized involvement of ventral tegmental-striatoac- 
cumbal pathways in craving and impaired control over 
alcohol consumption, it is not possible from this experi- 
ment to implicate directly this or associated circuits in the 
mediation of the observed effects of haloperidol on the 
primary outcome measures. These effects could, for ex- 
ample, result from interference with dopaminergic neu- 
rotransmission through the classically described reward or 
pleasure circuits involving mesocortical (tegmental-fron- 
tal) dopaminergic projections, the hypothalamus, the 
amygdala, and septa1 areas, without producing a down- 
stream effect within the fronto-striato-pallido-thalamo- 
frontal loop via the nucleus accumben~ .~ .~ ' .~~  Future stud- 
ies will be necessary to link the neuropharmacological 
mechanisms of craving and impaired control in humans 
with specific anatomic regions. 
Additionally, the results of this study do not allow the 
conclusion that craving and impaired control over alcohol 
drinking are exclusively modulated by dopaminergic sys- 
tems. Past studies have shown that other neurotransmitter 
systems-for example, the ~pioidergic~~ and serotonergic 
systemsZ4-are also associated with alcohol consumma- 
tory behaviors. Taken together, the data strongly support 
that the regulation of alcohol consumption involves an 
interaction between dopaminergic and other neurotrans- 
mitter systems; extensive interactions between dopami- 
nergic and opioidergic systems in the ventral tegmental 
area and nucleus accumbens, for example, are well-de- 
The relative absence of significant observed and re- 
ported side effects from haloperidol (with the exception of 
reported sedation) and the relative inability of subjects to 
differentiate injected haloperidol from saline were unex- 
Dected. We auestioned. therefore, whether this finding 
collected the same information at the same time periods 
relative to injection as in the alcohol study. This experi- 
ment was also a randomized-crossover (2 days apart), 
double-blind, placebo-controlled study. Subjects in this 
experiment did not receive alcohol; all BACs at the start 
of the experiments were 0. Institutional review board 
approval was also obtained for this study. 
Results of the companion study showed that, at the first 
assessment following the injection (assessment I), there 
were no significant differences between the alcoholic sub- 
jects and normal controls in motor tone, ability of the 
subject to identify accurately the injected material (the 
agent administered was misclassified by the normal sub- 
jects in 38% of cases at this assessment), or changes on 
any items of the assessment questionnaire. At assessment 
3, 50% of the control subjects misclassified the adminis- 
tered agent. Because the alcoholic subjects received alcohol 
following the first postinjection assessment and the control 
subjects did not, further comparison of outcome measures 
beyond the first postinjection assessment was not possible. 
The results of the companion study suggest, therefore, that 
the relative lack of observed and reported side effects from 
the injected haloperidol in the alcoholic subjects is not 
unique to this population and does not necessarily reflect 
the abnormal D-2 postsynaptic receptor sensitivity de- 
scribed in animal models of alcoholism. 
In conclusion, pretreatment with haloperidol produced 
favorable changes in subjectively rated alcohol craving 
and difficulty resisting drinking, and also decreased the 
amount consumed of optionally available alcohol without 
causing undesirable side effects. In addition to the research 
implications of these findings previously discussed, these 
results also suggest that low doses of D-2 antagonists taken 
orally in response to strong desires to drink may, in certain 
cases, reduce impaired control over drinking in the am- 
bulatory setting. Although the risk of serious dystonic 
reactions and tardive dyskinesia associated with low doses 
of intermittently administered D-2 antagonists is 
it will be important to determine whether there are specific 
subtypes of heavy drinkers for which administration of a 
D-2 antagonist might carry a particularly favorable risk- 
benefit ratio before the widespread use of these agents can 
be recommended in this population. The recent develop- 
ment of dopamine antagonists that lack many of the 
undesirable neurological effects of the conventional agents 
offers additional hope that a useful role for the dopamine 
antagonists in the treatment of chronic, heavy drinking 
might ultimately be found. 
might reflect ;he altered dopaminergic neuronal activity 
or abnormal D-2 postsynaptic receptor sensitivity de- 
scribed in animal models of a lc~hol i sm.~~-~ '  To explore 
this possibility further, We performed a companion study 
in which we administered 0.020 mg/kg haloperidol intra- 
venously to 16 normal, nonalcoholic control subjects and 
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